Verastem, Inc. Notes Payable, Fair Value Disclosure
Verastem, Inc. (VSTM) had Notes Payable, Fair Value Disclosure of $76.33 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Financial Instruments, Financial Liabilities, Balance Sheet Groupings
us-gaap:NotesPayableFairValueDisclosure · last filed 2026-03-04
- 2025-12-31: Notes Payable, Fair Value Disclosure $76.33M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $76.33M 10-K · filed 2026-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |